Journal of medicinal and pharmaceutical chemistry 2012-02-23

Pyridone methylsulfone hydroxamate LpxC inhibitors for the treatment of serious gram-negative infections.

Justin I Montgomery, Matthew F Brown, Usa Reilly, Loren M Price, Joseph A Abramite, Joel Arcari, Rose Barham, Ye Che, Jinshan Michael Chen, Seung Won Chung, Elizabeth M Collantes, Charlene Desbonnet, Matthew Doroski, Jonathan Doty, Juntyma J Engtrakul, Thomas M Harris, Michael Huband, John D Knafels, Karen L Leach, Shenping Liu, Anthony Marfat, Laura McAllister, Eric McElroy, Carol A Menard, Mark Mitton-Fry, Lisa Mullins, Mark C Noe, John O'Donnell, Robert Oliver, Joseph Penzien, Mark Plummer, Veerabahu Shanmugasundaram, Christy Thoma, Andrew P Tomaras, Daniel P Uccello, Alfin Vaz, Donn G Wishka

Index: J. Med. Chem. 4th ed., 55 , 1662-1670, (2012)

Full Text: HTML

Abstract

The synthesis and biological activity of a new series of LpxC inhibitors represented by pyridone methylsulfone hydroxamate 2a is presented. Members of this series have improved solubility and free fraction when compared to compounds in the previously described biphenyl methylsulfone hydroxamate series, and they maintain superior Gram-negative antibacterial activity to comparator agents.

Related Compounds

  • 3-Pyridylboronic a...

Related Articles:

A new access to 3-substituted-1(2H)-isoquinolone by tandem palladium-catalyzed intramolecular aminocarbonylation annulation.

2012-04-07

[Org. Biomol. Chem. 13th ed., 10 , 2683-2691, (2012)]

Synthesis and biological evaluation of novel amprenavir-based P1-substituted bi-aryl derivatives as ultra-potent HIV-1 protease inhibitors.

2012-03-01

[Bioorg. Med. Chem. Lett. 5th ed., 22 , 1976-1979, (2012)]

Copper-mediated sequential cyanation of aryl C-B and arene C-H bonds using ammonium iodide and DMF.

2012-02-08

[J. Am. Chem. Soc. 5th ed., 134 , 2528-2531, (2012)]

Phosphine-free Suzuki-Miyaura cross-coupling in aqueous media enables access to 2-C-aryl-glycosides.

2012-04-06

[Org. Lett. 7th ed., 14 , 1728-1731, (2012)]

Design and characterization of optimized adenosine A₂A/A₁ receptor antagonists for the treatment of Parkinson's disease.

2012-02-09

[J. Med. Chem. 3rd ed., 55 , 1402-1417, (2012)]

More Articles...